Global Cervical Cancer Diagnostics and Therapeutics Market- Segmented by Diagnostic Test, Method, End-Users, Therapy, and Geography 2017 - 2022

  • ID: 4388644
  • Report
  • Region: Global
  • 205 pages
  • Mordor Intelligence
1 of 3
The global cervical cancer market was valued at USD 2,140 million in 2015 and is expected to grow at a CAGR of 2-5% during the period from 2015 to 2021.

Cervical cancer is generally characterized by the abnormal growth of cancerous cells in the tissues of the cervix, and it may manifest itself as a squamous-cell carcinoma or adenocarcinoma. According to the World Health Organization (WHO), cervical cancer accounts for the death of more than 270,000 women annually, primarily in the developing countries. With the increasing use of cervical cancer diagnostic tests such as pap smear tests, HPV testing, and colposcopy for early detection, the market is highly competitive with a high growth rate.

Global Cervical Cancer Diagnostics and Therapeutics Market-Market Dynamics

The advent of technologically advanced computer-guided screening tests for cervical cancer in order to reduce the rate of false-negative results and improved accuracy are expected to contribute to the growth of the cervical cancer diagnostic tests market during the forecast period, from 2014 to 2021.


Some factors contributing to the growth of the market are:

Rising prevalence of cervical cancer

Favorable government initiatives

Funding to increase disease awareness

Increase of pipeline cervical cancer screening tests

Aging population

Increasing consumer awareness


Some factors limiting the growth of the market are:

Cost of screening tests

Availability of HPV vaccines

Uncertain reimbursement rates

Changes in regulatory guidelines

The global cervical cancer diagnostic and therapeutic market is segmented on the basis of diagnostics test (Pap smear test, HPV testing, colposcopy, cervical cancer biopsy), methods (molecular method, cytopathological method, physical method), end-users (hospitals, laboratories, independent physicians, clinics, and others), therapies (surgery, radiation therapy, chemotherapy and others) and geography (North America, Asia-Pacific, Europe, Middle East & Africa and Latin America). North America is expected to account for almost 49% of the total market share by 2020.

Major Companies in the Sector Include:

This Report Offers:

Market definition along with identification of key drivers and restraints for the market.

Market analysis with region-specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.

Identification and analysis of the macro and micro factors that affect the industry on both a global and regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

An ideal source material for industry consultants, manufacturers and other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.
Note: Product cover images may vary from those shown
2 of 3
1. Introduction
1.1 Study Deliverables
1.2 Market Definition
1.3 Sizing Units
1.4 Base Currency
1.5 Review and Forecast Period Years
1.6 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Analysis Methodology
2.3 Econometric Forecast Model
2.4 Research Assumptions
3. Executive Summary
4. Key Inferences
5. Market Overview and Industry Trends
5.1 Current Market Scenario
5.2 Applications of Cervical Cancer diagnostics and therapeutics
5.3 Technology Overview
5.4 New Developments
5.5 Industry Value-Chain Analysis
5.6 Product Life-Cycle Analysis
5.7 Product Benchmarking
5.8 Investment Analysis
5.8 Porter’s Five Forces
5.8.1 Bargaining Power of Suppliers
5.8.2 Bargaining Power of Consumers
5.8.3 Threat of New Entrants
5.8.4 Threat of Substitute Products and Services
5.8.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing prevalence of cervical cancer
6.1.2 Increasing incidences of weakened immune system
6.1.3 High use of cervical cancer diagnostic tests
6.1.4 Long-term use of oral contraceptive pills
6.1.5 Rapid spread of human papillomavirus (HPV) infection
6.1.6 Favorable government initiatives and funding
6.1.7 Lifestyle-related factors
6.2 Market Restraints
6.2.1 High cost of cancer therapeutics
6.2.2 Changes in regulatory guidelines for cervical cancer screening
6.2.3 Use of HPV vaccines
6.2.4 Uncertain reimbursement rates
6.3 Key Challenges
6.4 Current Opportunities in the Market
7. Market Segmentation
7.1 By End-Users
7.1.1 Hospitals
7.1.2 Clinical laboratories
7.1.3 Healthcare centers
7.2 Diagnostic tests
7.2.1 Pap smear test
7.2.2 HPV testing
7.2.3 Colposcopy
7.2.4 Loop Electrosurgical Excision Procedure
7.2.5 Biopsy
7.2.6 Endocervical Curettage
7.3 Screening methods
7.3.1 Molecular method
7.3.2 Cytopathological method
7.3.3 Physical method
7.4 Therapy
7.4.1 Surgery
7.4.2 Radiation therapy
7.4.3 Chemotherapy
7.4.4 Vaccines
7.5 By Geography
7.5.1 North America Introduction US Canada Rest of North America
7.5.2 Europe Introduction France UK Germany Russia Italy Spain Rest of Europe
7.5.3 Asia-Pacific Introduction India China Japan Australia South Korea Rest of Asia-Pacific
7.5.4 Middle East and Africa (MEA) Introduction UAE Saudi Arabia Israel Rest of the MEA
7.5.5 Latin America Introduction Brazil Argentina Mexico Rest of Latin America
8. Competitive Landscape
8.1 Merger and Acquisition Analysis
8.2 Patent Analysis
8.3 The Challengers
9. Company Profiles
9.1 Abbott Diagnostics
9.2 Becton Deckinson and Company
9.3 Roche
9.4 Qiagen
9.5 Siemens Healthcare
9.6 Dendreon Corporation
9.7 Otsuka Pharmaceuticals
9.8 Merck
9.9 GlaxoSmithKline PLC
9.10 Advaxis Immunotherapies
9.11 Bionor Pharma
10. Analyst Outlook for Investment Opportunities
11. Future Outlook of the Market
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown